High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib
نویسندگان
چکیده
منابع مشابه
[High-dose, few fractions radiotherapy for brain metastases].
From November 1976 through September 1981, 28 patients with brain metastases received the conventional therapy and 9 patients received a high-dose, few fractions radiotherapy. There were two types of deaths—eurological and systemic death. In the conventional therapy group, neurological death occurred in 61% of all cases, but no neurological death was observed in the high dose radiotherapy...
متن کاملFocal 3D conformal high-dose hypofractionated radiotherapy for brain metastases.
The optimal management of patients with few brain metastases is complex. On one hand, stereotactic radiation therapy is a keystone of treatment but is only applicable to highly selected patients fulfilling specific criteria who have access to an adequate radiation unit. On the other, whole-brain radiation therapy may improve survival, but deleterious effects on neurocognitive functions are well...
متن کاملDosimetric comparison of two different whole brain radiotherapy techniques in patients with brain metastases: How to decrease lens dose?
Background: Palliative whole brain radiotherapy (WBRT) has been the standard treatment for brain metastases. Ionizing radiation is known to be one of the most potent cataractogenic agents. We aimed to evaluate two different radiotherapy techniques with respect to the doses received by the organs at risk (OAR) in patients with brain metastasis who undergone WBRT. Materials and Methods: Ten conse...
متن کاملAspergillosis Superinfection as a Cause of Death of Crizotinib-Induced Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy
Crizotinib is an efficacious and well-tolerated drug in the management of ALK-positive lung cancer. Crizotinib treatment, however, is rarely complicated by the occurrence of acute interstitial lung disease (ILD) that is often fatal. There is no treatment for this serious adverse event. We report a female non-small cell lung cancer patient who developed ILD after a few days of crizotinib therapy...
متن کاملCrizotinib may be used in Lewis lung carcinoma: a novel use for crizotinib.
Lung cancer accounts for 13% (1.6 million) of the total cases and 18% (1.4 million) of the deaths in 2008. Crizotinib (PF-02341066) is identified as an ATP competitive small-molecular inhibitor for anaplastic lymphoma kinase (ALK). The US Food and Drug Administration (FDA) approved crizotinib to be used for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC in 2011...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2013
ISSN: 1556-0864
DOI: 10.1097/jto.0b013e31829cebbb